It was a 65-month median time between the prior malignancy and the CML diagnosis for the primary malignancies group. Other groups included nonmelanoma skin cancer and a group of patients with CML as the initial malignancy.
Results showed that a history of prior malignancy did not lead to a decreased chance of survival – a good sign for those living with the disease who are using TKI therapy as their treatment.
“The results of the current study indicate that survivors of prior malignancies who develop CML as a second (or later) malignancy may have a similarly excellent outcome with TKI therapy as patients for whom CML is their first malignancy,” the study said. Jorge E. Cortes of the University of Texas MD Anderson Cancer Center led the study. “In fact, these data stress the importance of the control of other comorbid conditions after the diagnosis and treatment of CML.”
